BioLineRx Ltd. (BLRX)

Market Cap	54.17M
Revenue (ttm)	4.80M
Net Income (ttm)	-60.61M
Shares Out	82.51M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,025
Open	0.662
Previous Close	0.640
Day's Range	0.631 - 0.680
52-Week Range	0.610 - 2.530
Beta	0.93
Analysts	Strong Buy
Price Target	12.50 (+1,804.04%)
Earnings Date	May 22, 2024

About BLRX

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infection...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2011
• Employees: 79
• Stock Exchange: NASDAQ
• Ticker Symbol: BLRX

Analyst Forecast

According to 2 analysts, the average rating for BLRX stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 1,804.04% from the latest price.

Price Target

$12.5

(1,804.04% upside)

Analyst Consensus: Strong Buy